Genscript Biotech Corporation filed its monthly return for the period ended 31 March 2026, detailing modest equity movements driven by employee incentive programmes.

Authorised Share Capital • Unchanged at 5.00 billion ordinary shares with a par value of USD 0.001, equivalent to authorised capital of USD 5.00 million.

Issued Share Capital • Total issued shares (excluding treasury shares) rose by 1.53 million to 2.19 billion, a 0.07 % dilution versus the February closing balance. • The company confirmed that its public float comfortably meets the Hong Kong Main Board’s minimum 25 % requirement.

Breakdown of Share Issuances 1. Share Options – 217,000 shares were issued upon option exercises under the Post-IPO Share Option Scheme, reducing outstanding options to 25.42 million. – Gross proceeds from these exercises totalled HKD 0.69 million.

2. Share Awards – 1.31 million shares were allotted for share awards granted under a scheme approved on 21 June 2024.

Other Capital Movements • No warrants, convertibles, share repurchases or treasury-share transfers occurred during the month.

With the latest allotments, Genscript Bio’s issued share base stands at 2.19 billion shares, while authorised capacity remains ample at 5.00 billion shares.